Author

Chau Tran

Denali Therapeutics (United States)Primary ORCID profile (0009-0008-1993-6745 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Chau TraniD1 paper · University of Zurich

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Anastasia G. HenryiD· 1 shared Buyankhishig TsogtbaatariD· 1 shared Di Jiang· 1 shared Eric A. MackliniD· 1 shared Jillian H. KlussiD· 1 shared Meng FangiD· 1 shared Michael A. SchwarzschildiD· 1 shared Ritesh RaviiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Anastasia G. HenryORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CSF glucosylsphingosine is a central readout of GCase impairment across genetic and sporadic Parkinson’s disease

Jillian H. Kluss, Di Jiang, Shan V. Andrews, Ritesh Ravi, Romeo D. Maciuca, Buyankhishig Tsogtbaatar, Chau Tran, Meng Fang, Eric A. Macklin, Anastasia G. Henry, Michael A. Schwarzschild, Sarah Huntwork

This study measures CSF glucosylsphingosine (GlcSph) levels in Parkinson’s disease patients and finds elevated GlcSph in GBA1 carriers and sporadic PD, indicating central GCase pathway impairment.

bioRxiv · Jun 22, 2026 · PreprintMolecular Biology